



Published in final edited form as:

Circ Res. 2017 January 06; 120(1): 11–12. doi:10.1161/CIRCRESAHA.116.310214.

Defining the Complexity of the Junctional Membrane Complex

Barry London, MD, PhD

Division of Cardiovascular Medicine, University of Iowa, Iowa City, IA

Keywords

t-tubules; heart failure; sarcoplasmic reticulum; excitation-contraction coupling

Each heart beat in every cardiac myocyte begins with the surface membrane depolarization during an action potential that opens L-type Ca^{2+} channels and allows the influx of a small amount of extracellular Ca^{2+} that triggers a larger release of Ca^{2+} from the intracellular store, the sarcoplasmic reticulum (SR), through Ryanodine Receptors (RyR2).^{1–2} This process, known as Ca^{2+} -induced Ca^{2+} -release (CICR), is the primary mechanism underlying excitation-contraction coupling (ECC) in the heart. Cardiac myocytes are relatively large cells, and efficient cardiac function requires not only the rapid sequential activation of contraction between cells but also the simultaneous activation of the contractile apparatus within each cell. To accomplish this, adult cardiac myocytes localize L-type Ca^{2+} channels in deep membrane invaginations known as T-Tubules, located along the Z-lines adjacent to the SR Ca^{2+} release channels in highly ordered structures known as dyads. The potential importance of these organized junctional membrane complexes has been defined during the last decade using in situ imaging techniques that show their loss in pathological conditions including myocardial infarction and heart failure.³

Additional proteins essential for the structure and function of the junctional membrane complex have been identified. Junctophilin-2 (JPH2) connects the T-tubular and SR membranes and is downregulated in a number of models of heart failure.^{4–6} Of greater note, JPH2 disruption leads to heart failure in rodent models, JPH2 overexpression protects against the transition from hypertrophy to failure in a rodent model with thoracic aortic constriction, and mutations in JPH2 cause hypertrophic cardiomyopathy. More recently, the protein bridging integrator-1' (Bin1), also known as M-amphiphysin-2, has been shown to be essential for the development and stability of T-tubules.⁷ The identity and roles of other proteins in the junctional membrane complex are less clear.

Striated Muscle Preferentially Expressed Protein Kinase (SPEG) is a serine/threonine kinase in the myosin light chain kinase family.⁸ SPEG β and SPEG α , a shorter isoform lacking 854 amino acids at the N-terminal end, are both expressed in the heart. SPEG interacts with

Corresponding Author: Barry London, M.D., Ph.D., Division of Cardiovascular Medicine, University of Iowa Carver College of Medicine, E315-GH, 200 Hawkins Drive, Iowa City, IA 52242, (319) 356-2750 (phone), (319) 353-6343 (fax), barry-london@uiowa.edu.

Disclosures:

None

myotubularin (MTM1), and SPEG mutations are rare causes of dilated cardiomyopathy.⁹ Targeted deletion of SPEG in the mouse leads to dilated cardiomyopathy and early postnatal mortality.¹⁰ In addition, cardiac progenitor cells of *Speg*^{-/-} mice are abnormal, and the neonatal defects in *Speg*^{-/-} mice can be rescued through the intrauterine injection of wild type cardiac progenitor cells into the developing heart.¹¹ Thus, although SPEG clearly plays a role in cardiac development and function, a role in Ca²⁺ handling has not previously been identified.

In this issue of *Circulation Research*, Quick et al. use MS/MS mass spectrometry to search for novel proteins that co-immunoprecipitate with both RyR2 from the hearts of wild type mice and Jph2 from the hearts of transgenic mice overexpressing Jph2.¹² They successfully identified *Speg* α and *Speg* β as novel components of the junctional membrane complex with isoform-specific binding to RyR2 and Jph2. They go on to show that SPEG is downregulated in human heart failure, and to engineer a tamoxifen-inducible cardiac-specific *Speg* knockout mouse that demonstrates the rapid onset of T-tubular disarray followed by heart failure, a lower SR Ca²⁺ content with increased spark frequency with no change in *Serca2a*-mediated SR Ca²⁺ uptake, and no change in Jph2 expression but a marked decrease in Jph2 phosphorylation. Taken together, these studies provide strong evidence that SPEG plays a critical role in both the structure and function of cardiac T-tubules and the RyR2-mediated Ca²⁺ release that they direct.

This well-conceived and elegant study is important for several reasons. First, it identifies a novel and important role for SPEG in the junctional membrane complex, and suggests a previously unknown functional role for JPH2 phosphorylation. Second, the work provides further evidence that T-tubular disarray can causally contribute to the pathogenesis of heart failure. Finally, it provides insight into Ca²⁺-dependent mechanisms leading to heart failure that are independent of changes in SERCA2a expression and function, and that may not be amenable to therapies aimed at raising SERCA2a such as AAV-SERCA2a gene delivery to the heart.¹³

As would be expected, the identification of SPEG in the junctional membrane complex raises as many questions as it answers. What (if any) are the specific roles of the *Speg* α and *Speg* β isoforms? Which residue(s) of JPH2 is (are) phosphorylated, and is the decrease in JPH2 phosphorylation causally related to the development of T-tubular disarray and heart failure (as opposed to an indirect effect through phosphorylation of another target)? Does phosphorylation of JPH2 alter its proteolytic cleavage? Does SPEG interact with BIN1, and does myotubularin play a role in the junctional membrane complex?^{7,9} Do polymorphisms in SPEG predispose to heart failure and/or arrhythmias? Do mutations in SPEG cause inherited forms of sudden death?

While SPEG was the only new protein identified by the MS/MS screen using Jph2 and RyR2, it is likely that other unidentified proteins are playing a role in the junctional membrane complex. These proteins may bind to either JPH2 or RYR2. Alternately, future studies could now use SPEG as bait to identify other members of the protein complex. During the last several years, our understanding of the junctional membrane complex has increased. The manuscript of Quick et al. has contributed to our improved understanding.

That said, we do not yet know just how complex the junctional membrane will turn out to be.

Acknowledgments

Sources of funding:

None

References

1. Wagner S, Maier LS, Bers DM. Role of sodium and calcium dysregulation in tachyarrhythmias in sudden cardiac death. *Circ Res.* 2015; 116:1956–1970. [PubMed: 26044250]
2. Kline CF, Mohler PJ. Evolving form to fit function: cardiomyocyte intercalated disc and transverse-tubule membranes. *Curr Top Membr.* 2013; 72:121–158. [PubMed: 24210429]
3. Chen B, Zhang C, Guo A, Song L-S. In situ single photon confocal imaging of cardiomyocyte T-tubule system from Langendorff-perfused hearts. *Front Physiol.* 2015; 6:134. [PubMed: 25999861]
4. van Oort RJ, Garbino A, Wang W, Dixit SS, Landstrom AP, Gaur N, De Almeida AC, Skapura DG, Rudy Y, Burns AR, Ackerman MJ, Wehrens XH. Disrupted junctional membrane complexes and hyperactive ryanodine receptors after acute junctophilin knockdown in mice. *Circulation.* 2011; 123:979–988. [PubMed: 21339484]
5. Beavers DL, Landstrom AP, Chiang DY, Wehrens XHT. Emerging roles of junctophilin-2 in the heart and implications for cardiac diseases. *Cardiovasc Res.* 2014; 103:198–205. [PubMed: 24935431]
6. Guo A, Zhang X, Ramesh V, Chena B, Zhang C, Kutschke WJ, Weiss RM, Franzini-Armstrong C, Song L-S. Overexpression of junctophilin-2 does not enhance baseline function but attenuates heart failure development after cardiac stress. *Proc Natl Acad Sci (USA).* 2014; 111:12240–12245. [PubMed: 25092313]
7. Caldwell JL, Smith CER, Taylor RF, Kitmitto A, Eisner DA, Dibb KM, Trafford AW. Dependence of cardiac transverse tubules on the BAR Domain Protein Amphiphysin II (BIN-1). *Circ Res.* 2014; 115:986–996. [PubMed: 25332206]
8. Hsieh CM, Fukumoto S, Layne MD, Maemura K, Charles H, Patel A, Perrella MA, Lee ME. Striated muscle preferentially expressed genes alpha and beta are two serine/threonine protein kinases derived from the same gene as the aortic preferentially expressed gene-1. *J Biol Chem.* 2000; 275:36966–36973. [PubMed: 10973969]
9. Agrawal PB, Pierson CR, Joshi M, Liu X, Ravenscroft G, Moghadaszadeh B, Talabere T, Viola M, Swanson LC, Halilo lu G, Talim B, Yau KS, Allcock RJ, Laing NG, Perrella MA, Beggs AH. SPEG interacts with myotubularin, and its deficiency causes centronuclear myopathy with dilated cardiomyopathy. *Am J Hum Genet.* 2014; 95:218–226. [PubMed: 25087613]
10. Liu X, Ramjiganesh T, Chen YH, Chung SW, Hall SR, Schissel SL, Padera RF Jr, Liao R, Ackerman KG, Kajstura J, Leri A, Anversa P, Yet SF, Layne MD, Perrella MA. Disruption of striated preferentially expressed gene locus leads to dilated cardiomyopathy in mice. *Circulation.* 2009; 119:261–268. [PubMed: 19118250]
11. Liu X, Hall SR, Wang Z, Huang H, Ghanta S, Di Sante M, Leri A, Anversa P, Perrella MA. Rescue of neonatal cardiac dysfunction in mice by administration of cardiac progenitor cells in utero. *Nat Commun.* 2015; 6:8825. [PubMed: 26593099]
12. Quick AP, Wang Q, Philippen LE, Barreto-Torres G, Chiang DY, Beavers DL, Wang G, Khalid M, Reynolds JO, Campbell HM, Showell J, McCauley MD, Scholten A, Wehrens XH. Striated Muscle Preferentially Expressed Protein Kinase (SPEG) Is Essential for Cardiac Function by Regulating Junctional Membrane Complex Activity. *Circ Res.* 2016 In Press.
13. Greenberg B, Butler J, Felker GM, Ponikowski P, Voors AA, Desai AS, Barnard D, Bouchard A, Jaski B, Lyon AR, Pogoda JM, Rudy JJ, Zsebo KM. Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised,

multinational, double-blind, placebo-controlled, phase 2b trial. *Lancet*. 2016; 387:1178–1186.
[PubMed: 26803443]

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript